Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Oct 14;26(1):122.
doi: 10.1186/s40001-021-00587-7.

The efficacy and safety of high-flow nasal cannula therapy in patients with COPD and type II respiratory failure: a meta-analysis and systematic review

Zhiping Xu #  1 , Lingxia Zhu #  1 , Jingye Zhan  1 , Lijun Liu  2
Affiliations
Meta-Analysis

The efficacy and safety of high-flow nasal cannula therapy in patients with COPD and type II respiratory failure: a meta-analysis and systematic review

Zhiping Xu et al. Eur J Med Res. .

Abstract

Background: High-flow nasal cannula (HFNC) and noninvasive ventilation (NIV) have been used for the treatment of COPD and respiratory failure in clinical settings. We aimed to evaluate the efficacy and safety of HFNC therapy in patients with COPD and type II respiratory failure, to provide evidence to the clinical COPD management.

Methods: We searched Cochrane et al. databases up to Dec 31, 2020 for randomized controlled trials (RCTs) on the use of HFNC therapy in patients with COPD and type II respiratory failure. Two researchers independently screened the literature according to the inclusion and exclusion criteria, and evaluated the quality of the literature and extracted data. We used Revman5.3 software for statistical analysis of collected data.

Results: A total of 6 RCTs involving 525 COPD and type II respiratory failure patients. Meta-analyses indicated that compared with NIV, HFNC could significantly reduce PaCO2 level (MD = - 2.64, 95% CI (- 3.12 to - 2.15)), length of hospital stay ((MD = - 1.19, 95 CI (- 2.23 to - 0.05)), the incidence of nasal facial skin breakdown ((OR = 0.11, 95% CI (0.03-0.41)). And there were no significant differences between the two groups in PaO2 ((MD = 2.92, 95% CI (- 0.05 to 5.90)), incidence of tracheal intubation ((OR = 0.74, 95% CI (0.34-1.59)) and mortality (OR = 0.77, 95% CI (0.28-2.11)).

Conclusions: HFNC is more advantageous over NIV in the treatment of COPD and type II respiratory failure. Future studies with larger sample size and strict design are needed to further elucidate the role of HFNC in COPD and respiratory failure.

Keywords: COPD; HFNC; Respiratory failure; Review; Treatment; Ventilation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
The PRISMA flow diagram of study selection
Fig. 2
Fig. 2
Risk of bias graph
Fig. 3
Fig. 3
Risk of bias summary
Fig. 4
Fig. 4
The forest plots for synthesized outcomes
Fig. 5
Fig. 5
The forest plots for synthesized outcomes
See this image and copyright information in PMC

References

    1. Labaki WW, Rosenberg SR. Chronic obstructive pulmonary disease. Ann Intern Med. 2020;173(3):ITC17–ITC32. doi: 10.7326/AITC202008040. - DOI - PubMed
    1. Rabe KF, Watz H. Chronic obstructive pulmonary disease. Lancet. 2017;389(10082):1931–1940. doi: 10.1016/S0140-6736(17)31222-9. - DOI - PubMed
    1. Gredic M, Blanco I, Kovacs G, Helyes Z, Ferdinandy P, Olschewski H, Barbera JA, Weissmann N. Pulmonary hypertension in chronic obstructive pulmonary disease. Br J Pharmacol. 2021;178(1):132–151. doi: 10.1111/bph.14979. - DOI - PubMed
    1. Duffy SP, Criner GJ. Chronic obstructive pulmonary disease: evaluation and management. Med Clin North Am. 2019;103(3):453–461. doi: 10.1016/j.mcna.2018.12.005. - DOI - PubMed
    1. Hattab Y, Alhassan S, Balaan M, Lega M, Singh AC. Chronic obstructive pulmonary disease. Crit Care Nurs Q. 2016;39(2):124–130. doi: 10.1097/CNQ.0000000000000105. - DOI - PubMed

MeSH terms